A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

Genentech, Inc.450 enrolled

Overview

This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Enrollment

450

Conditions

Psoriasis

Interventions

Raptiva (efalizumab)DRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Previous participation in Study ACD2600g * For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study Exclusion Criteria: * Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to Efalizumab

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.